Tsukalov, Ilya
Sánchez-Cerrillo, Ildefonso
Rajas, Olga
Avalos, Elena
Iturricastillo, Gorane
Esparcia, Laura
Buzón, María José http://orcid.org/0000-0003-4427-9413
Genescà, Meritxell http://orcid.org/0000-0001-6413-3812
Scagnetti, Camila
Popova, Olga
Martin-Cófreces, Noa
Calvet-Mirabent, Marta
Marcos-Jimenez, Ana http://orcid.org/0000-0002-7606-3580
Martínez-Fleta, Pedro
Delgado-Arévalo, Cristina
de los Santos, Ignacio
Muñoz-Calleja, Cecilia
Calzada, María José
González Álvaro, Isidoro
Palacios-Calvo, José
Alfranca, Arantzazu http://orcid.org/0000-0002-3732-5816
Ancochea, Julio http://orcid.org/0000-0001-7451-4133
Sánchez-Madrid, Francisco
Martin-Gayo, Enrique http://orcid.org/0000-0002-2619-6086
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (CIBERINFECC, CIBERINFECC, CIBERINFECC, CIBERCV)
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (PID2021-127899OB-I00, PID2021-127899OB-I00)
Comunidad de Madrid (Inmunovacter REACT-UE, INMUNOVACTER REACT-EU, INMUNOVACTER REACT-EU)
Ministerio de Economía y Competitividad (PDC2021-121719-I00, PID-2020-120412RB-I00)
Article History
Received: 14 April 2023
Accepted: 22 February 2024
First Online: 7 March 2024
Competing interests
: I.G.A. reports the following competing interests: personal fees from Lilly and Sanofi; personal fees and non-financial support from BMS; personal fees and non-financial support from Abbvie; research support, personal fees and non-financial support from GEBRO Pharma; non-financial support from MSD, Pfizer and Novartis, not related to the submitted work. The rest of the authors have no additional competing interests.